TagMedicare

The CMS has renewed its position on Alzheimer’s future drugs that also target the amyloid proteins that are likely to cause the disease. If these drugs undergo a traditional approval process rather than an accelerated approval process, patients will not need to be in a randomized, controlled trial. Instead, they may be on a patient register that monitors how patients behave while taking...